• Home
  • About Us
    • About Us
    • Subscribe
    • Privacy Policy
  • Advertise
    • Advertise On IP Watch
    • Editorial Calendar
  • Videos
  • Links
  • Help

Intellectual Property Watch

Original news and analysis on international IP policy

  • Copyright
  • Patents
  • Trademarks
  • Opinions
  • People News
  • Venues
    • Bilateral/Regional Negotiations
    • ITU/ICANN
    • United Nations – other
    • WHO
    • WIPO
    • WTO/TRIPS
    • Africa
    • Asia/Pacific
    • Europe
    • Latin America/Caribbean
    • North America
  • Themes
    • Access to Knowledge/ Open Innovation & Science
    • Food Security/ Agriculture/ Genetic Resources
    • Finance
    • Health & IP
    • Human Rights
    • Internet Governance/ Digital Economy/ Cyberspace
    • Lobbying
    • Technical Cooperation/ Technology Transfer
  • Health Policy Watch

UNITAID Report On Delinking R&D Costs From Medicines Prices

28/02/2016 by Intellectual Property Watch Leave a Comment

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Delinkage of research and development costs from medicines prices could “vastly expand” access to medicines by drastically dropping costs of the knowledge component of health products, innovative medicines R&D facility UNITAID says in a new report.

The report, entitled: “An economic perspective on delinking the cost of R&D from the price of medicines,” [pdf] was published on 26 February. The report summary from UNITAID is available here.

“The report, which touches on IP issues, asks how best to separate the costs of research and development for vaccines, medicines and diagnostics from their prices – a concept known as “delinkage,” according to a UNITAID source.

“The study focuses on how to finance research in pharmaceuticals, while respecting intellectual property rights of companies, without burdening consumers with unnecessary costs,” UNITAID said in the report summary. “The authors use economic models to compare the financial implications of delinkage with the current market situation; where medicines tend to be sold by patent-holders at prices higher than competitive generic prices.”

“The paper presents models of the likely economic effects of delinkage in a range of hypothetical scenarios: in a single country, in multiple countries, and in markets with incomes segmented within countries, among others,” it said. “It concludes that delinkage can vastly expand access to medicines as the costs of the knowledge component of health products falls to zero.

According to UNITAID, “the authors argue that under delinkage, governments can better:

  • Optimize allocation of R&D funding between direct funding and providing incentives for development
  • Better fund and reward upstream R&D
  • Eliminate the waste of resources associated with marketing of patented medicines”

The full UNITAID report is available here [pdf]. The report was written by public health expert James Love with support from UNITAID, the report states.

UNITAID was established in 2006 by Brazil, Chile, France, Norway and the United Kingdom to “provide an innovative approach to global health.” Its mission is “finding new ways to prevent, treat and diagnose HIV/AIDS, tuberculosis and malaria more quickly, more cheaply and more effectively.”

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to email this to a friend (Opens in new window)
  • Click to print (Opens in new window)

Related

Creative Commons License"UNITAID Report On Delinking R&D Costs From Medicines Prices" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Filed Under: IP-Watch Briefs, IP Policies, Language, Themes, Venues, English, Finance, Health & IP, Innovation/ R&D, Patents/Designs/Trade Secrets, WHO

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  • Email
  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • Vimeo
My Tweets

IPW News Briefs

Saudis Seek Alternative Energy Partners Through WIPO Green Program

Chinese IP Officials Complete Study Of UK, European IP Law

Perspectives on the US

In US, No Remedies For Growing IP Infringements

US IP Law – Big Developments On The Horizon In 2019

More perspectives on the US...

Supported Series: Civil Society And TRIPS Flexibilities

Civil Society And TRIPS Flexibilities Series – Translations Now Available

The Myth Of IP Incentives For All Nations – Q&A With Carlos Correa

Read the TRIPS flexibilities series...

Paid Content

Interview With Peter Vanderheyden, CEO Of Article One Partners

More paid content...

IP Delegates in Geneva

  • IP Delegates in Geneva
  • Guide to Geneva-based Public Health and IP Organisations

All Story Categories

Other Languages

  • Français
  • Español
  • 中文
  • اللغة العربية

Archives

  • Archives
  • Monthly Reporter

Staff Access

  • Writers

Sign up for free news alerts

This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy

Copyright © 2021 · Global Policy Reporting

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.